Short Interest in Briacell Therap (NASDAQ:BCTX) Increases By 108.0%

Briacell Therap (NASDAQ:BCTX) was the target of a large growth in short interest in the month of April. As of April 30th, there was short interest totaling 472,347 shares, a growth of 108.0% from the April 15th total of 227,052 shares. Currently, 6.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 182,536 shares, the days-to-cover ratio is presently 2.6 days.

Briacell Therap Price Performance

NASDAQ BCTX traded up $0.33 during mid-day trading on Monday, hitting $3.35. The company’s stock had a trading volume of 209,669 shares, compared to its average volume of 389,658. Briacell Therap has a 52-week low of $2.98 and a 52-week high of $37.20. The stock’s fifty day simple moving average is $4.14 and its two-hundred day simple moving average is $6.23. The firm has a market capitalization of $24.28 million, a P/E ratio of -0.14 and a beta of 1.26.

Briacell Therap (NASDAQ:BCTX) last released its quarterly earnings results on Tuesday, March 10th. The company reported ($2.58) earnings per share for the quarter.

Institutional Investors Weigh In On Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Flagship Harbor Advisors LLC acquired a new position in shares of Briacell Therap (NASDAQ:BCTX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned 0.21% of Briacell Therap at the end of the most recent quarter. Hedge funds and other institutional investors own 15.42% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research report on Monday, April 20th. Wall Street Zen raised Briacell Therap from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Briacell Therap currently has a consensus rating of “Sell”.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.